Eligibility Module

Eligibility Module

The Eligibility Module contains detailed information about who can participate in the clinical trial. This includes eligibility criteria, age restrictions, gender requirements, healthy volunteer status, and study population descriptions, helping researchers understand who is eligible to participate in the study.

Eligibility Module path is as follows:

Study -> Protocol Section -> Eligibility Module

Eligibility Module


Ignite Creation Date: 2025-12-25 @ 12:08 AM
Ignite Modification Date: 2025-12-25 @ 12:08 AM
NCT ID: NCT04674358
Eligibility Criteria: Inclusion Criteria: * 18 years of age (either gender and any race); * Reported history of dry eye for at least 6 months prior to Visit 1; * Reported history of use or desire to use eye drops for dry eye symptoms within 6 months of Visit 1 Exclusion Criteria: * Clinically significant slit lamp findings at Visit 1 that may include active blepharitis, meibomian gland dysfunction (MGD), lid margin inflammation, or active ocular allergies that require therapeutic treatment, and/or in the opinion of the investigator may interfere with study parameters; * Diagnosis of an ongoing ocular infection (bacterial, viral, or fungal), or active ocular inflammation at Visit 1; * Contact lens use within 7 days of Visit 1 or anticipate using contact lenses during the trial; * Eye drop use within 2 hours of Visit 1; * Previous laser-assisted in situ keratomileusis (LASIK) surgery within the last 12 months; * Cyclosporine 0.05% or 0.09% or lifitegrast 5.0% ophthalmic solution use within 90 days of Visit 1; * Be receiving systemic corticosteroid therapy (not including inhaled corticosteroids) within 14 days of Visit 1 or anticipate such therapy throughout the study period; * Planned ocular and/or lid surgeries over the study period or any ocular surgery within 6 months of Visit 1; * Temporary punctal plugs during the study that have not been stable within 30 days of Visit 1
Healthy Volunteers: False
Sex: ALL
Minimum Age: 18 Years
Study: NCT04674358
Study Brief:
Protocol Section: NCT04674358